Artiva (NASDAQ: ARTV) SVP gets 46,000 RSUs, 1,521 shares withheld

(Neutral)

Form Type

Rhea-AI Filing Summary

Artiva Biotherapeutics reported that SVP of Research and Development Heather Raymon received a grant of 46,000 shares of common stock in the form of restricted stock units under the company’s 2024 Equity Incentive Plan. On the same date, 1,521 shares at $4.00 per share were withheld to cover income tax obligations linked to restricted stock unit vesting, leaving Raymon with 151,323 directly owned shares.

Insider Trade Summary

Net Buyer: 44,479 shares

Net Buy 2 txns

Insider Raymon Heather

Role SVP, Research and Development

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	46,000	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	1,521	$4.00	$6K

Holdings After Transaction: Common Stock — 151,323 shares (Direct)

Footnotes (2)

F1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
F2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/18/2026 - 06:51 PM

FAQ

What insider transactions did Artiva Biotherapeutics (ARTV) report for Heather Raymon?

Artiva Biotherapeutics reported that SVP Heather Raymon received 46,000 restricted stock units and had 1,521 shares withheld. The withheld shares, at $4.00 each, were used to satisfy income tax obligations related to the vesting of restricted stock unit awards.

How many Artiva Biotherapeutics (ARTV) shares does Heather Raymon own after these transactions?

After the reported transactions, SVP Heather Raymon directly owns 151,323 shares of Artiva Biotherapeutics common stock. This reflects the 46,000-share restricted stock unit grant and the withholding of 1,521 shares to cover income tax obligations on vested restricted stock unit awards.

What type of equity award did Artiva Biotherapeutics (ARTV) grant to Heather Raymon?

Heather Raymon received a restricted stock unit award covering 46,000 shares of Artiva Biotherapeutics common stock. The award was granted under the company’s 2024 Equity Incentive Plan, which provides equity-based compensation to key employees and aligns their interests with shareholders.

Why were 1,521 Artiva Biotherapeutics (ARTV) shares disposed of in Heather Raymon’s Form 4?

The Form 4 shows a disposition of 1,521 shares at $4.00 per share as a tax-withholding transaction. These shares were withheld by Artiva Biotherapeutics to satisfy income tax obligations associated with the vesting of restricted stock unit awards previously granted to Heather Raymon.

Were Heather Raymon’s Artiva Biotherapeutics (ARTV) transactions open-market buys or sells?

The transactions were not open-market trades. The 46,000 shares represent a restricted stock unit grant with no purchase price, and the 1,521-share disposition at $4.00 per share reflects shares withheld by the company to cover tax obligations on vesting restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raymon Heather

(Last)

(First)

(Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Research and Development

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/15/2026		A		46,000⁽¹⁾	A	$0	152,844	D
Common Stock	02/15/2026		F		1,521⁽²⁾	D	$4	151,323	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

	/s/ Andrew Cronauer, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR